FDA Approves First Generic Hormone Therapy Patch and Novel Chronic Hepatitis B Treatment

The U.S. Food and Drug Administration (FDA) has approved the first generic version of Climara Pro (estradiol and levonorgestrel transdermal system), a once-weekly hormone therapy patch for women with an intact uterus. Additionally, the FDA has authorized the first-of-its-kind chronic Hepatitis B treatment, Hibsago, which is injected under the skin for up to 24 weeks alongside existing medication. These approvals aim to expand patient access to important therapies.